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Abstract: The consumption of sweet beverages, including sugar-sweetened beverages (SSB), artificial-
sweetened beverages (ASB) and fruit juices (FJ), is associated with the risk of different cardiometabolic
diseases. It may also be linked to the development of certain types of tumors. We carried out a
systematic review and meta-analysis of observational studies aimed at examining the association
between sweet beverage intake and cancer risk. Suitable articles published up to June 2020 were
sourced through PubMed, Web of Science and SCOPUS databases. Overall, 64 studies were identified,
of which 27 were selected for the meta-analysis. This was performed by analyzing the multivariable-
adjusted OR, RR or HR of the highest sweet beverage intake categories compared to the lowest one.
Random effects showed significant positive association between SSB intake and breast (RR: 1.14,
95% CI: 1.01–1.30) and prostate cancer risk (RR: 1.18, 95% CI: 1.10–1.27) and also between FJs and
prostate cancer risk (RR: 1.03, 95% CI: 1.01–1.05). Although the statistically significant threshold
was not reached, there tended to be positive associations for the following: SSBs and colorectal and
pancreatic cancer risk; FJs and breast, colorectal and pancreatic cancer risk; and ASBs and pancreatic
cancer risk. This study recommends limiting sweet beverage consumption. Furthermore, we propose
to establish a homogeneous classification of beverages and investigate them separately, to better
understand their role in carcinogenesis.
Keywords: systematic review; meta-analysis; cohort; case-control; sugar-sweetened beverages;
artificial sweetened beverages; fruit juice; cancer
1. Introduction
The consumption of sweet beverages has increased in the last decades, with sugar-
sweetened beverages (SSB) and artificially sweetened beverages (ASB) among the most
widely consumed [1,2]. SSBs contain high levels of sugar that usually come from added
sucrose or high fructose corn syrup (HFCS). Another type of sweet beverage is fruit juice
(FJ), including fresh and commercial FJs and nectars. Despite their natural and healthy
image, they contain high levels of sugar in the form of fructose. Although whole fruit also
contains fructose, the fiber present limits the insulin response and increases satiety [3].
High sugar consumption may contribute to excessive energy intake, leading to long-term
weight gain [4], higher risk of type 2 diabetes [5] and cardiovascular disease [6].
It has been demonstrated that obesity and type 2 diabetes are well-known risk factors
for cancer [7–9]. Diets high in added sugar usually result in weight gain and an increase in
adiposity-related metabolic parameters, insulin resistance, bioactivity of steroid hormones,
oxidative stress and inflammation, which finally leads to cancer development and pro-
gression [9]. The International Agency for Research on Cancer (IARC) reported as strong
evidence that excess body fat is a major risk factor for many cancers, including esophageal,
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pancreatic, colorectal, post-menopausal breast, endometrial, renal, ovarian, gallbladder,
hepatic and gastric cardia, among others [10].
High sugar intake impairs glucose and insulin tolerance and augments insulin and
insulin-like growth factor (IGF) levels. Insulin and IGF are major determinants of prolifer-
ation and apoptosis, and may therefore influence carcinogenesis [11]. Beverages high in
sugar, including SSBs and FJs, have high glycemic indexes [12] which is also suggested to
be linked to cancer [13]. Moreover, both caloric and noncaloric sweet palatable substances
have been demonstrated to activate the dopaminergic reward system. This can trigger
addictive-like behaviors, which might be responsible for increased body fat [14]. ASBs
contain low or non-caloric sweeteners (e.g., aspartame) and have been marked as healthier
alternatives to SSBs. However, some studies have suggested that ASBs are also deleterious
as regards obesity [15] and type 2 diabetes risk [5]. Moreover, it has also been suggested that
long-term consumption of aspartame, used in many ASBs, might be carcinogenic [16]. As-
partame in liquids can quickly break down into methanol, and the subsequent metabolized
formaldehyde is a documented carcinogenic substance [17].
In light of all this evidence, the association between consumption of sweet beverages
and cancer risk has been investigated and reviewed by different studies. A meta-analysis
from 2014 studied the association between SSB/ASB consumption and overall and specific
cancer but no links were found [18]. Likewise, a 2019 meta-analysis did not find any
significant association between SSB/ASB intake and pancreatic cancer risk [19]. However,
the two mentioned studies did not perform a separate analysis of SSBs and ASBs which
might have elucidated their particular role on cancer. A pooled analysis from 2012 [20]
suggested a modest positive association between SSB intake and the risk of pancreatic
cancer. Another similar study from 2010 [21] showed no significant association with
colon cancer risk. A qualitative review of longitudinal studies from 2018 [22] reported
inconsistent results for SSB/FJ intake and cancer risk. A recent French publication [23]
reported a positive association between FJs and overall cancer risk. Regarding ASB intake,
their results for breast, colorectal and prostate cancer risk were nonsignificant. However,
another study [24] showed an increased risk for leukemia in the total population as well as
for non-Hodgkin lymphoma and multiple myeloma in men only.
Evidence suggests that the link between sweet beverages consumption and cancer
onset is biologically plausible. However, each type of beverage may have different mecha-
nisms of action and different roles in cancer onset. Therefore, our study aimed to investigate
these associations, by conducting separate analyses for SSB, ASB and FJ intake and cancer
incidence. We analyzed case-control and cohort studies and performed a meta-analysis
when feasible. Through this study we intend to update and develop a better understanding
of the association between the consumption of sweet beverages and cancer incidence, a dis-
ease that caused 9.6 million deaths in 2018, a figure projected to nearly double by 2040 [25].
2. Materials and Methods
2.1. Search Method for Identification of Studies
This study was conducted according to the Preferred Reporting Items for System-
atic Reviews Meta-Analysis (PRISMA) guidelines. To identify the suitable articles, we
searched in PubMed, Web of Science and SCOPUS databases up to 31 June 2020, using
the following keywords: (((((“soft drinks”[All Fields] OR “sugary drinks”[All Fields])
OR “sugary beverages”[All Fields]) OR “fruit juice”[All Fields]) OR “sugar-sweetened
beverages”[MeSH Terms]) OR “artificially sweetened beverages”[MeSH Terms]) AND
((((“neoplasms”[MeSH Terms] OR “neoplasm”[All Fields]) OR “cancer”[All Fields]) OR
“cancers”[All Fields]) OR “tumor”[All Fields]). We also applied search filters by article
type (excluding books, reviews, systematic reviews and meta-analyses) and by species
(including only humans). Moreover, reference lists of included manuscripts and relevant
reviews were examined for any possible unidentified study. The search process was limited
to English and Spanish languages.
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2.2. Eligibility Criteria and Data Extraction
Eligible cohort and case-control studies were selected if they met the following criteria:
(1) included adult participants free of cancer (if prospective) or with no history of previous
cancer (if case-control) at recruitment, except for nonmelanoma skin cancer; (2) overall
or site-specific cancer incidence as an outcome; and (3) estimated and reported hazard
ratio (HR), risk ratio (RR) or odds ratio (OR) with 95% confidence interval (CI) for the link
between any type of sweet beverages and any type of cancer incidence. The exclusion
criteria were: (1) participants with previous cancer history or currently undergoing cancer
treatment; (2) cancer survival and cancer mortality as an outcome; and (3) duplicated
studies. The following data were extracted: first author’s name, publication year, study
name, country, age and sex of the participants, study sample size, number of cases and
controls, follow-up duration, cancer site, type of exposure and amount of intake, dietary
assessment methods, confounders’ adjustment and HR/RR/OR with 95% CI for the larger
degree of adjustment. When time-varying results were reported, those related to baseline
data were extracted.
Three review authors independently performed the literature search, study selection
and data extraction (FL, MG-L, and PU). Disagreements were discussed between all authors
until a consensus was reached.
2.3. Quality Assessment of Included Studies
Two independent review authors (FL and MG-L) examined the methodological quality
of the individual studies using the Risk Of Bias In Non-randomized Studies—of Exposures
(ROBINS-E) [26] tool for cohort studies and the Newcastle–Ottawa Scale (NOS) [27] adapted
for case-control studies. The ROBINS-E tool evaluates the risk of bias by assessing different
domains: confounding variables, selection of participants into the study, classification of
exposures, departures from intended exposures, missing data, measurement of outcomes
and selection of the reported result. Low, moderate or serious risk of bias was established
in each study considering all domains. The NOS assesses the selection of groups (0–4 stars),
adequacy of comparability between groups (adjustment for confounders) (0–2 stars) and
ascertainment of the exposure of interest for case–control studies (0–3 stars). For selection
domain, we considered studies with 0–1, 2–3 and 4 stars as serious bias risk, moderate bias
risk and high-quality risk, respectively. For comparability between groups, we considered
those with 0, 1 and 2 as serious, moderate, and low bias risk, respectively. And finally, for
ascertainment of exposure, we considered those 0, 1–2 and 3 as serious risk, moderate risk
and low bias risk, respectively. In both tools, when data were not enough for judgment, the
domain was classified as ‘no information’.
2.4. Data Synthesis and Statistical Analysis
The first obstacle that we had to overcome was the lack of a unique definition for bev-
erages and a variety of other terms. In this text, the following group terms are used to gen-
eralize these products: SSB for sugar-sweetened beverages (regular soft drinks/sodas, and
non-diet soft drinks/sodas), ASB for artificially sweetened beverages (low and noncaloric
soft drinks/sodas, and diet soft drinks/sodas) and FJ for fruit juices. In addition, two other
terms are used: SB for sweetened beverages that includes both SSBs and ASBs; SFJ for
high-sugar (added or natural) beverages that includes both SSBs and FJs. The quantity
of each beverage was provided mostly as categories of frequency of consumption, either
in amount (mL or g/day) or serving sizes (cans for SSBs and ASBs, glasses for FJs). To
unify the data, we converted the categories to mL/day, based on the study-specific serving
size for each beverage. When the serving size was not reported, we referred the national
data of each study. Thus, we considered one can equal to 330 mL and one glass equal
to 200 mL for European countries [28], one can equal to 360 mL and one glass equal to
240 mL for the United States [29], and one can equal to 375 mL for Australia [30]. One US
study [31] expressed consumption as grams of sugar, and we weighed up an average of
10.5 g of sugar per 100 mL of SSB and an average of 9.6 g of sugar per 100 mL of FJ. This
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was calculated based on the sugar content of different commercially available products of
popular brands [32].
Prior to the analysis, the selected studies were classified by outcome (cancer incidence
by site) and exposure (SB, SSB, ASB, FJ and SFJ). Data were summarized in a narrative
manner and a meta-analysis was performed only if at least three studies reported data
for the same exposure and outcome. In the meta-analysis, results for the total number of
participants were considered. Separate analyses were considered (e.g., European-American
and African-American women) when the article did not report indices for total population.
In the same manner, if studies reported data for specific beverages (e.g., caffeinated and non-
caffeinated SSBs), results for the total beverage group (e.g., total SSBs) were weighted up.
Despite having extracted data on fruit and vegetables juices together, for the meta-analysis
we considered the studies that indicated FJs as the predominant beverage consumed. The
meta-analysis was performed by pooling the multivariable-adjusted RR/HR/OR of the
highest category of the exposure versus the lowest one, and random effects models were
assumed. If statistical outliers were identified, secondary analyses were performed (without
outliers) to remove possible sources of heterogeneity. An outlier was considered when
its 95% CI lied outside the 95% CI of the pooled effect. To further explain heterogeneity,
we performed subgroup and sensitive analyses, dividing studies according to design
(cohort/case-control), country (US/non-US, mostly European), level of overall risk of bias
(serious/low-moderate) and beverage intake category (high vs. non-consumer/high vs.
low). We used Cochran’s Q, I2 and Tau2 statistics to measure between-study heterogeneity.
The statistical analysis was performed with the Metafor package [33] of the R software,
version 4.0.1. P values < 0.05 were considered statistically significant.
3. Results
3.1. Literature Search and Study Characteristics
The study selection process according to PRISMA guidelines is reported in Figure 1.
In total, 869 potential publications were identified from the databases (PubMed, Web of
Science and SCOPUS) and other sources. After removing duplicates, 596 articles were
selected, from which 435 were excluded based on titles and 26 on abstracts. Of 135 eligible
articles, 71 were excluded due to the following reasons: 59 did not report risk index
for sweet beverages and cancer incidence, 3 full-texts were not available, 7 considered
other outcomes, 1 case-control study included controls with cancer at recruitment and
1 publication was not in English or Spanish. Finally, 64 studies were included in the
systematic review, 27 cohort [23,24,28,31,34–56] and 37 case-control studies [57–93]. Of
these, 27 studies were meta-analyzed.
Of the included studies, 29 were performed in the United States (US), 17 in Europe, 6 in
Asia, 5 in Canada, 3 in Australia, 2 in Latin-America, 1 in Egypt and 1 was multinational
(Italy, Spain, Poland, Northern Ireland, India, Cuba, Canada, Australia and Sudan). They
usually included both male and female participants. Ages ranged from 18 to 97 years. The
27 cohort studies were published between 2003 and 2020 and enrolled 4,458,056 participants
in total, of which 30,646 developed cancer. Mean duration of the follow-up in cohort studies
varied from 2 to 20 years. The 37 case-control studies were published between 1985 and
2019. In total, they enrolled 20,827 cancer cases and 34,315 controls. Most of the controls
were selected from the general population.
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in Asia, 5 in Canada, 3 in Australia, 2 in Latin-America, 1 in Egypt and 1 was multina-
tional (Italy, Spain, Poland, Northern Ireland, India, Cuba, Canada, Australia and Su-
dan). They usually included both male and female participants. Ages ranged from 18 to 
97 years. The 27 cohort studies were published between 2003 and 2020 and enrolled 
4,458,056 participants in total, of which 30,646 developed cancer. Mean duration of the 
follow-up in cohort studies varied from 2 to 20 years. The 37 case-control studies were 
published between 1985 and 2019. In total, they enrolled 20,827 cancer cases and 34,315 
controls. Most of the controls were selected from the general population. 
Sweet beverage consumption in both cohort and case-control studies was expressed 
as categorical or continuous variables. Exposure assessment was collected using food 
frequency questionnaires (FFQ), 24-h dietary recalls (24-H DR), dietary questionnaires 
(DQ), interviews, or surveys. Among all the studies, 37 types of cancer were considered 
as an outcome and 4 cohorts reported data for overall cancer risk, including different 
types of cancer [23,50,52,54]. In most of the studies, the outcome was confirmed by a 
medical diagnosis. Overall characteristics of the included studies are summarized in Ta-
ble 1. Results of the meta-analysis for the random-effect model are summarized in Table 2 
and for the subgroup analysis in Table S1. 
3.2. Sweet Beverages and Risk of Breast Cancer 
Nine publications reported data on breast cancer, four case-control [57,58,69,80] and 
five cohort studies [23,51–53,55]. In the meta-analysis with six publications, including 
four cohort studies [23,52,53,55] and two case-controls [57,80], a significant positive as-
sociation between high SSB consumption and breast cancer risk was observed (RR: 1.14, 
95% CI: 1.0–1.3) (Table 2). No associations were found for FJ intake (Table 2). Marzbani et 
al. [58] reported a positive association with SBs (OR: 2.8, 95% CI: 1.9–4.3), but no associa-
tions were found for ASBs. Subgroup analyses for SSB consumption did not explain 
further heterogeneity (Table S1). 
Figure 1. Prisma diagram.
Sweet beverage consumption in both cohort and case-control studies was expressed
as categorical or continuous variables. Exposure assessment was collected using food
frequency questionnaires (FFQ), 24-h dietary recalls (24-H DR), dietary questionnaires
(DQ), interviews, or surveys. Among all the studies, 37 types of cancer were considered
as an outcome and 4 cohorts reported data for overall cancer risk, including different
types of c ncer [23,50,52,54]. In ost of the studies, the outcome was confirmed by a
medical diagnosis. Overall characteristics of the included studies are summarized in
Table 1. Results of the meta-analysis for the random-effect model are summarized in
Table 2 and for the subgroup analysis in Table S1.
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Table 1. Overall characteristic of the included studies.
Breast Cancer (Breast, Pre- and Post-Menopausal)
Source Country, Study Name Cancer Type Study Design Population Follow-Up(Years) Cases
Age (Mean/SD
or Range) Sex (%)
Dietary Assessment
Method











20–75 F (100) 125-item FFQ
SSB: ≥152 vs. <152 mL/day OR: 0.97 (0.74–1.27) (AA)
OR:1.31 (0.91–1.89) (EA)
OR: 1.17 (0.79–1.74) (AA)
OR: 0.95 (0.58–1.56) (EA)
OR: 0.76 (0.51–1.12) (AA)
OR: 2.05 (1.13–3.7) (EA)
Age, ethnicity, country,
education, age at menarche,
menopause and first birth,
MS, parity, BF status, history
of benign breast disease,
family history of BC, HRT, OC
use, BMI, and study site.
Pre-M 797 SSB: ≥152 vs. <152 mL/day
Post-M 761 SSB: ≥152 vs. <152 mL/day








42.2/14.4 F (78) 24H-DR
SFJ: >123 vs. <38.1 mL/day (cut-off)
SFJ: increase by 100 mL/day
SSB: >57.1 vs. <13.6 mL/day (cut-off)
SSB: increase by 100 mL/day
ASB: >11.6 vs. <4.6 mL/day (cut-off)
ASB: increase by 10 mL/day
FJ: >81.9 vs. <17.0 mL/day (cut-off)
FJ: increase by 100 mL/day
SFJ: >123 vs. <38.1 mL/day (cut-off)
SFJ: increase by 100 mL/day
SSB: >57.1 vs. <13.6 mL/day (cut-off)
SSB: increase by 100 mL/day
ASB: >11.6 vs. <4.6 mL/day (cut-off)
ASB: increase by 10 mL/day
FJ: >81.9 vs. <17.0 mL/day (cut-off)
FJ: increase by 100 mL/day
SFJ: >123 vs. <38.1 mL/day (cut-off)
SFJ: increase by 100 mL/day
SSB: >57.1 vs. <13.6 mL/day (cut-off)
SSB: increase by 100 mL/day
ASB: >11.6 vs. <4.6 mL/day (cut-off)
ASB: increase by 10 mL/day
FJ: >81.9 vs. <17.0 mL/day (cut-off)





























Hirvonen et al., 2006
[51] France, SUVIMAX Breast Cohort
4396
6.6 95 35–60 F (100) 24H-DR FJ: >150 mL/day vs. none RR: 1.29 (0.80–2.09)
Age, smoking, number of
children, OC use, family
history of BC, and MS.
Makarem et al., 2018
[52] US Breast Cohort
3184
4 128 54.3 F (53) FFQ
SFJ: >324 vs. <135 mL/day (cut-off)
SSB: >51.4 mL/day vs. none




Age, smoking, BMI, EI,
alcohol, PA, education, MS, nº
of live births, WC, DM and
CVD, antioxidant use, energy
from fat, and diet soda intake.
Marzbani et al., 2019
[58] Iran Breast HB case-control 620 212 40.2 F (100)
11-item healthcare
form
SB 7: favorable intake vs. ≤1
time/month OR: 2.8 (1.9–4.3) Age, education, and BMI
McLaughlin et al., 1992
[69] US Breast PB case-control 3234 1617 56.7 F (100) SQ-interview SB
2: ever vs. never OR: 1.08 (0.92–1.26)
Age, alcohol, country, race,
MS, age at first live birth,
diagnosis of benign cancers,
and family history of BC.
Potischman et al., 2002
[80] US Breast PB case-control 2019 568 20–44 F (100) 100-item FFQ SSB: ≥320 mL/day vs. none OR: 1.09 (0.8–1.5)
Age at diagnosis, study site,
race, education, alcohol
consumption, years of OC
use, smoking, BMI, and EI.
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Table 1. Cont.
Romanos-Nanclares






33.0 (median) F (100) FFQ
SSB: >47.1 vs. <11 mL/day HR: 1.36 (0.74–2.50)
Age, height, family history of
BC, smoking, PA, BMI, age at
menarche and menopause,
MS, HRT, number of
pregnancies >6 month and
before 30 years old, months of
BF, alcohol, education, DM,
GI, EI, U-P food and coffee
consumption, and Med-diet
adherence.
Pre-M 57 SSB: ≥11 mL/day vs. none HR: 1.16 (0.66–2.07)
Post-M 43 SSB: >47.1 vs. <11 mL/day HR: 2.12 (1.01–4.41)
Hodge et al., 2018 [54] Australia, MCCS Post-M Cohort 35,59319 946 54.6 F (100) 121-item FFQ
SSB: ≥200 vs. <6.7 mL/day




country of birth, alcohol
intake, smoking, PA,
Med-diet score, and sex. ASB
also for SSB consumption and
WC.








21–69 F (100) FFQ
SSB: ≥250 mL/day vs. none
SSB: ≥250 mL/day vs. none




Age, geographic region of
residence, EI, smoking, family
history of BC, education, MS,
OC use, parity, HRT, BMI,
alcohol, PA, and sedentary
time.
Colorectal and Rectal Cancer
Source Country, Study Name Cancer Type Study Design Population Follow-Up(Years) Cases
Age (Mean/SD
or Range) Sex (%)
Dietary Assessment
Method





2010 [88] Qatar Colorectal HB case-control 428 146 53.4 M (58) DQ SB: ≥330 vs. ≤47.1 mL/day OR: 1.62 (1.19–2.17) Not reported
Chazelas et al., 2019
[23]
France Colorectal Cohort 101,2575.1 (median) 166
42.2 (14.4) F (78) 24H-DR
SFJ:
>123 vs. <38.1 mL/day (F);
>141.7 vs. <46.1 mL/day (M) (cut-off)
increase by 100 mL/day
SSB:
>57.1 vs. <13.6 mL/day (F);
>65.5 vs. < 14.0 mL/day (M) (cut-off)
increase by 100 mL/day
ASB:
>11.6 vs. <4.6 mL/day (F);
>7.9 vs. < 2.7 mL/day (M) (cut-off)
increase by 10 mL/day
FJ:
>81.9 vs. <17.0 mL/day (F);
>97.8 vs. <19.9 mL/day (M) (cut-off)
increase by 100 mL/day
HR: 1.07 (0.63–1.80)









Hodge et al., 2018 [54] Australia, MCCS Colorectal Cohort 35,59319 1055 54.6 M/F 121-item FFQ
SSB: ≥200 vs. <6.7 mL/day




country, alcohol, smoking, PA,
Med-diet score, and sex. ASB
also for SSB consumption and
WC.
Makarem et al., 2018
[52] US Colorectal Cohort
3184
4 68 54.3 F (53) FFQ
SFJ: >362.6 vs. <154.3 mL/day (cut-off)
SSB: >180 vs. <25.7 mL/day (cut-off)




Age, smoking, BMI, EI,
alcohol, PA, education, MS, nº
of live births, WC, DM and
CVD, antioxidant use, energy
from fat, and diet soda intake.
Mahfouz et al., 2014
[89] Egypt Colorectal HB case-control
450
1 150 <20–>60 F (52) DQ
SB: daily vs. not daily
FJ: daily vs. not daily
OR: 4.6 (1.9–11.01)
OR: 0.18 (0.09–0.36) Not reported
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Table 1. Cont.
Pacheco et al., 2019 [56] US Colorectal Cohort 99,79820.1 (median) 1318 52.0 (13.5) F (100) FFQ SSB: ≥60 mL/day vs. never/rare HR: 1.14 (0.86–1.53)
Age, BMI, EI, smoking,
alcohol, family history of CR
polyps, multivitamin use, and
HT.
Tayyem et al., 2018 [90] Jordan Colorectal HB case-control 5012 220 52 F (51) Q-DQ
SB: daily vs. rarely
OJ: daily vs. rarely
OR: 1.39 (0.73–2.63)
OR: 1.07 (0.45–2.55)
Age, sex, work status, income,
PA, marital status, EI,
education, other diseases, and
history of CR cancer.
Theodoratou et al.,
2014 [91] Scotland Colorectal PB case-control
4838
7.0 2062 64.3 M/F FFQ
SSB: increase by 330 mL/day
FJ: increase by 200 mL/day
OR: 1.12 (1.05–1.19)
OR: 1.19 (1.11–1.27)
Age, sex, BMI, PA, family
history of CR cancer, EI,
NSAIDs, eggs, FJ, SSB, white
fish, coffee, and magnesium
intake.
Murtaugh et al., 2004
[92] US Rectal PB case-control
2157
4 952 30–79 M (57) Interview
SSB: yes vs. no (M)
SSB: yes vs. no (F)
ASB: yes vs. no (M)
ASB: yes vs. no (F)
J: >449 vs. ≤58.3 mL/day (M);







Age, PA, EI, and dietary fiber
and calcium intake.
Esophageal Cancers (Esophagus-Gastric Junction, Esophageal Adenocarcinoma, Squamous Cell Carcinoma)
Source Country, Study Name Cancer Type Study Design Population Follow-Up(Years) Cases
Age (Mean/SD
or Range) Sex (%)
Dietary Assessment
Method









18–79 M (71) FF
SB 7: ≥375 mL/day vs. none
SSB 7: yes vs. no
ASB 7: yes vs. no
SB 7: ≥375 mL/day vs. none
SSB 7: yes vs. no
ASB 7: yes vs. no
SB 7: ≥375 mL/day vs. none
SSB 7: yes vs. no










Age, sex, BMI, EI, alcohol,
smoking, education,












SSB 7: ≥355 vs. 10.7 mL/day OR: 0.47 (0.29–0.76)
Age, sex, center, race, proxy
interview status, BMI, EI,
alcohol and meat intake,
cigarettes/day, education,
income, and frequency of
reflux symptoms.
SCC 206 SSB 7: ≥355 vs. 10.7 mL/day OR: 0.85 (0.48–1.52)





50–71 M (59) 124-item FFQ
SB: ≥355 vs. ≤355 mL/day HR: 1.11 (0.66–1.85) Age, sex, smoking, alcohol, EI,
BMI, education, ethnicity, PA,
and daily intake of fruit,
vegetables, red meat, and
white meat.
SCC 123 SB: ≥355 vs. ≤355 mL/day HR: 0.85 (0.46–1.56)
Stomach Cancers (Gastric Cardia, Gastric Noncardia)
Source Country, Study Name Cancer Type Study Design Population Follow-Up(Years) Cases
Age (Mean/SD
or Range) Sex (%)
Dietary Assessment
Method




Hodge et al., 2018 [54] Australia, MCCS Gastric cardia Cohort 35,59319 165 54.6 M/F 121-item FFQ
SSB: ≥200 vs. <6.7 mL/day




country, alcohol, smoking, PA,
Med-diet score, and sex. ASB
also for SSB consumption
and WC.
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Table 1. Cont.








SSB 7: ≥355 vs. <10.7 mL/day OR: 0.74 (0.46–1.16) Age, sex, center, race, proxy
interview status, BMI, EI,
alcohol and meat intake
cigarettes/day, education,
incomes, and frequency of
reflux symptoms.352 SSB
7: ≥355 vs. <10.7 mL/day OR: 0.65 (0.43–0.98)







50–71 M (59) 124-item FFQ
SB: ≤355 vs. ≥355 mL/day HR: 0.89 (0.55–1.45) Age, sex, smoking, alcohol, EI,
BMI, education, ethnicity, PA
and daily intake of fruit,
vegetables, and white meat.
224 SB: ≥355 vs. ≤355 mL/day HR: 0.75 (0.45–1.24)
Pancreatic Cancer
Source Country, Study Name Cancer Type Study Design Population Follow-Up(Years) Cases
Age (Mean/SD
or Range) Sex (%)
Dietary Assessment
Method




Bao et al., 2008 [42] US,NIH-AARP-DHS Pancreatic Cohort
487,922
7.2 1258 50–71 F (41) 124-item FFQ
SB: 816.9 mL/day (median) vs. none
SSB: 512.8 mL/day (median) vs. none




Age, sex, race, education,
BMI, alcohol, smoking, PA, EI,
and foliate intake. SSB and
ASB were mutually adjusted.
Chan et al., 2009 [76] US,SFB Pancreatic PB case-control 2233 532 21–85 M (53) 131-item FFQ
SB: ≥355 mL/day vs. none
SB 7: ≥355 mL/day vs. none
SSB 7: ≥355 mL/day vs. none
ASB 7: ≥355 mL/day vs. none






Age, sex, EI, BMI, race,
education, smoking, history
of DM, PA, red and white
meat, fruit and vegetables,
eggs, dairy, whole and refine
grained, and sweets. SSB and
ASB were mutually adjusted.
Gallus et al., 2011 [77] Italy Pancreatic HB case-control 9787 326 63 (median) M (53) FFQ SB
7: ≥150 vs. <150 mL/day OR: 1.02 (0.72–1.44)
Age, sex, study center,
education, BMI, smoking,
alcohol, EI, family history of
pancreatic cancer, and DM.
Gold et al., 1985 [78] US Pancreatic HB, PB case-control 676 274 66.1 F (53) Interview ASB: ever vs. never OR: 0.66 (0.38–1.2) Religion, occupation,smoking, and alcohol.
Larsson et al., 2006 [41] Sweden,SMC, COSM Pancreatic Cohort
77,797
7.2 131 60.8 F (45) FFQ SB: ≥500 mL/day vs. none HR: 1.93 (1.18–3.14)
Age, sex, education, smoking,
BMI, and EI.
Lyon et al.,
1992 [79] US Pancreatic PB case-control 512 149 40–79 M/F DQ SB (caff): ever vs. never OR: 1.31 (0.89–1.94) Unadjusted.
Mack et al., 1986 [81] US Pancreatic PB case-control 980 490 18–65 M (58) Proxy and directInterview SB
7: ≥1650 vs. <1320 mL/day RR: 2.6 (0.9–7.4) Not reported
Mueller et al., 2010 [43] China and Singapore,SCHS Pancreatic Cohort
60,524
14 140 56.5 F (56) FFQ
SB: ≥67.7 mL/day vs. none
J 5: ≥67.7 mL/day vs. none
HR: 1.87 (1.10–3.15)
HR: 1.31 (0.74–2.30)
Age, sex, smoking, BMI,
alcohol, EI, PA, DM,
education, added sugar, and
candy. SB and J were
mutually adjusted.
Nothlings et al., 2007




SSB: ≥151.4 mL/2000 kcal/day vs.
none
FJ: ≥120 vs. < 9.4 mL/2000 kcal/day
RR: 1.07 (0.82,1.41)
RR: 1.08 (0.83,1.41)
Age, sex, smoking, BMI, EI,
time on study, race, family
history of pancreatic cancer,






Pancreatic Cohort 477,20611.4 865 51 F (70) DQ- country specific
SB: >196.4 vs. 0.1–13.1 mL/day
SB: increase by 100 mL/day
SSB: >121.4 vs. 0.1-4.5 mL/day
SSB: increase by 100 mL/day
ASB: >92.2 vs. 0.1-2.0 mL/day
ASB: increase by 10 mL/day
FJ 6: >123.1 vs. 0.1-8.3 mL/day









Age, sex, smoking, BMI,
alcohol, EI, study center, PA,









379 53.7 F (65) FFQ SSB: <143.6 vs. > 11.2 mL/dayASB: <143.6 vs. > 11.2 mL/day
RR: 1.13 (0.81–1.58)
RR: 1.02 (0.79–1.32)
Age, sex, smoking, BMI,
follow-up cycle, PA, DM, and
other soft drink intake.
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Genitourinary Cancers (Prostate, Renal Cell, Urinary Bladder, Urothelial Cell)
Source Country, Study Name Cancer Type Study Design Population Follow-Up(Years) Cases
Age (Mean/SD
or Range) Sex (%)
Dietary Assessment
Method




Bruemmer et al., 1997
[60] US Bladder PB case-control 620 215 45–65
M (62) Interview SSB: >240 vs. < 8 mL/day
OR: 0.4 (0.2–1.1) (M)
OR: 5.7 (1.2–26.9) (F)
OR: 1.6 (0.7–3.6) (M) OR: 2.3
(0.8–6.3) (F)
Age, country, and smoking.
ASB: >240 < 8 mL/day
De Stefani et al., 2007
[61] Uruguay Bladder HB case-control 756 255 30–89 M (88) 64-item FFQ SB: ≥142 vs. <142 mL/day OR: 1.1 (0.7–1.7)
Age, sex, residence, education,
familiar history of UBC, BMI,
occupation, smoking, intake
of mate, coffee, tea, and milk.
Hemelt et al., 2010 [62] China Bladder HB case-control 7923 400 65.8 M (79) DQ
SB: consumers vs. none
FJ: daily vs. none
OR: 2.01 (1.10–3.68)
OR: 0.66 (0.26–1.66)
Age, sex, smoking, and
frequency and duration of
smoking.
Radosavljević et al.,
2003 [63] Serbia Bladder HB case-control 260 130 64.9 M (79) 101-item FFQ
SB: >15.7 mL/day (mean) vs. none
FJ: >11.6 mL/day (mean) vs. none
OR: 4.73 (2.72–8.18)
OR: 0.30 (0.18–0.50) Smoking
Turati et al., 2015 [64] Italy Bladder HB case-control 1355 665 67 (median) M (76) DQ SB 2: ≥47 mL/day vs. none OR: 1.04 (0.73–1.49)
Age, sex, study center, year of
interview, smoking,
education, alcohol, BMI, and
family history of UBC and
cystitis.
Wang, 2013 [65] US Bladder HB case-control 2306 1007 64.4 M (78) FFQ
SB: ≥255.6 mL/day vs. none
SSB: ≥126 mL/day vs. none




Age, sex, ethnicity, EI, and
smoking.
Chazelas et al., 2019
[23] France Prostate Cohort
101,257
5.1 (median) 291 42.2/4.4 M (100) 24H-DR
SFJ: >141.7 vs. <46.1 mL/day (cut-off)
SFJ: increase by 100 mL/day
SSB: >65.5 vs. <14.0 mL/day (cut-off)
SSB: increase by 100 mL/day
ASB: >7.9 vs. <2.7 mL/day (cut-off)
ASB: increase by 10 mL/day
FJ: >97.8 vs. <19.9 mL/day (cut-off)









Smoking, education, PA, BMI,
and height.
Drake et al., 2012 [35] Sweden,MDC Prostate Cohort
8128




SSB: 297.8 mL/day (median) vs. none
FJ: 200 mL/day (median) vs. none
HR: 1.13 (0.92–1.38)
HR: 0.99 (0.81–1.22)
Age, year of study entry, time
of data collection, EI, height,
WC, PA, smoking, education,
birth in Sweden, alcohol,
calcium and selenium intake,
and risk by death from all
causes except PC.
Ellison et al., 2000 [36] Canada,NCSS Prostate Cohort
3400
23 201 50–84 M (100) FFQ
SB 2: ≥100 mL/day vs. none
SB 2: ≥any vs. none
RR: 1.29 (0.74–2.26)
RR:1.09 (0.78–1.35)
Age, alcohol, smoking, BMI,
fiber, and EI.
Hodge et al., 2018 [54] Australia, MCCS Prostate Cohort 35,59319 433 54.6 M (100) 121-item FFQ
SSB: ≥200 vs. <6.7 mL/day




country of birth, alcohol,
smoking, PA, and Med-diet
score. ASB also for SSB
consumption and WC.
Jain et al., 1998 [66] Canada Prostate PB case-control 1253 617 69.8 M (100) Q-DH SB 2: >200 mL/day vs. none OR: 0.79 (0.53–1.17) Age, EI
Makarem et al., 2018
[52] US Prostate Cohort
3184
4 157 54.3 M (100) FFQ
SFJ: >401 vs. <212.1 mL/day (cut-off)
SSB: >180 vs. <25.7 mL/day (cut-off)




Age, smoking, BMI, EI,
alcohol, PA, education, WC,
DM, CVD, antioxidant use,
and energy from fat and diet
soda intake.
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Miles et al., 2018 [31] US Prostate Cohort 22,7209
1996 65.6 (5.9) M (100) FFQ SSB: >183 vs. <6 mL/day (cut-off)FJ: >190 vs. <24 mL/day (cut-off)
HR: 1.21 (1.06–1.39)
HR: 1.07 (0.94–1.22)
Age, sex, smoking, BMI, EI,
DM, education, race, family
history of PC, and PSA
screens.
Sharpe et al., 2002 [67] Canada Prostate PB case-control 875 399 61.5 M (100) Interviewsor DQ
SB 7: daily drank vs. never drank





Hodge et al., 2018 [54] Australia, MCCS Renal cell Cohort 35,59319 146 54.6 M/F 121-item FFQ
SSB: ≥200 vs. <6.7 mL/day




country of birth, alcohol,
smoking, PA, Med-diet score,
and sex. ASB also for SSB
consumption and WC
Hu et al., 2009 [68] Canada Renal cell PB case-control 6177 1138 20–80 M (51) FFQ
SB: >230 mL/day vs. none
SB: increase by 230 md
J: >236 vs. ≤23 mL/day





10-year age groups, province,
education, BMI, sex, EI,
smoking, intake of alcohol
meat, vegetables, and fruits.




248 53.7 F (65) FFQ
SB: ≥670 vs. <47.9 mL/day
SSB: increase by 335 mL/day
ASB: increase by 335 mL/day





BMI, EI, alcohol, smoking,
history of HT, DM,
multivitamin use, and parity.
Maclure and Willet,
1990 [70] US Renal cell PB case-control 430 203 30–>80 M (67) FFQ
SB: >480 vs. <68.6 mL/day
ASB: >480 vs. <68.6 mL/day




Age, sex, body weight/height,
EI, and education
Ros et al., 2011 [38]
10 European countries
† , EPIC
Urothelial cell Cohort 233,2369.3 513 25–70 F (71) DQ-country specific
SB: ≥99 vs. <8 mL/day (M);
≥20 vs. <8 mL/day (F)
FJ: ≥72 vs. <8 mL/day (M);
≥79 vs. 8 mL/day (F)
HR: 1.03 (0.83–1.30)
HR: 1.32 (1.05–1.66)
Smoking, EI from fat and
nonfat sources. Stratified by
age at entry, sex, and center.
Gynecological Cancers (Cervical, Endometrial, Epithelial Ovarian, Ovarian)
Source Country, Study Name Cancer Type Study Design Population Follow-Up(Years) Cases
Age (Mean/SD
or Range) Sex (%)
Dietary Assessment
Method




Herrero et al., 1991 [71] Colombia, Costa Rica,Mexico and Panama Cervical HB, PB case-control 2033 622 46.5 F (100) FFQ FJ: >240 vs. <0.8 mL/day OR: 0.90 (0.7–1.2)
Age, study site, age at 1st
intercourse, number of sexual
partners and pregnancies,
presence of HPV 16/18,
interval since last Pap smear,
and number of household
facilities.
Verreault et al. 1989
[72] US Cervical PB case-control 416 189 20–74 F (100) 66-items FFQ FJ: ≥ 355 vs. ≤ 48 mL/day RR: 0.3 (0.2–0.6)
Age, education, smoking,
frequency of Pap smears, use
of barrier and OC, history of
cervical-vaginal infection, age
at first intercourse, and
number of sexual partners.







61.6 F (100) FFQ
SFJ: >424.3 vs. ≤55.7 mL/day
SSB: >87.4 mL/day vs. none
ASB: >144 mL/day vs. none
FJ: >288 vs. ≤20.6 mL/day
SFJ: >424.3 vs. ≤55.7 mL/day
SSB: >87.4 mL/day vs. none
ASB: >144 mL/day vs. none









Age, smoking, BMI, PA,
alcohol, HRT, age at menarche
and at menopause, number of
live births, DM, and
coffee intake.Endometrial type II 89
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Table 1. Cont.





54.6 F (100) 121-item FFQ
SSB: ≥200 vs. <6.7 mL/day
ASB: ≥200 vs. <6.7 mL/day
SSB: ≥200 vs. <6.7 mL/day






country of birth, alcohol,
smoking, PA, Med-diet score,
and sex. ASB also for SSB
consumption and WC.Ovarian 130
King et al., 2013 [73] US Epithelial ovarian PB case-control 5957 205 >21 F (100) FFQ and Interview
SSB: ≥151.2 vs. <21.6 mL/2000
kcal/day
SSB: increase by 360 mL/day
OR: 1.31 (0.77–2.24)
OR: 1.63 (0.94–2.83)
Age, education, race, age at
menarche, MS, parity, OC use,
HRT, BMI, smoking, PA, DM,
tubal ligation, intake of fiber,
fat, and saturated fat.
Leung et al., 2016 [74] Canada Epithelial ovarian PB case-control 211111 524 40–79 F (100) FFQ and Interview SB: >9.9 mL/day vs. none OR: 0.97 (0.72–1.31)
Age, race, education, BMI,
smoking, alcohol, history of
ovarian/breast cancer, OC
use, parity, MS, HRT, and
study site.
Song et al., 2008 [75] US Epithelial ovarian PB case-control 20503 781 35–74 F (100) FFQ
SB 3 (caff): ≥720 mL/day vs. none




smoking, race, country, years





Hepatobiliary Cancers (Biliary Tract, Gallbladder, Liver)
Source Country, Study Name Cancer Type Study Design Population Follow-Up(Years) Cases
Age (Mean/SD
or Range) Sex (%)
Dietary Assessment
Method












51 F (70) DQ-country specific
SB: 282.9 mL/day vs. none
FJ 1: 171.7 mL/day vs. none
SB: 282.9 mL/day vs. none
FJ 1: 171.7 mL/day vs. none
SB: 282.9 mL/day vs. none
SB: increase by 300 mL/wk
SSB: increase by 330 mL/wk
ASB: increase by 330 mL/wk
FJ 1: 171.4 mL/day vs. none











BMI, alcohol, EI, PA, DM, and
education.IHBT 66
HCC 191








45–83 M (56) 96-item FFQ
SB: ≥400 mL/day vs. none
SB: ≥400 mL/day vs. none




Age, sex, education, smoking,
BMI, dietary protein intake,
and EI.
Hematologic Cancers (Leukemia, Lymphoma, Myeloma)
Source Country, Study Name Cancer Type Study Design Population Follow-Up(Years) Cases
Age (Mean/SD
or Range) Sex (%)
Dietary Assessment
Method














53.7 F (65) FFQ
SSB: ≥335 mL/day vs. none
ASB: ≥335 mL/day vs. none
SSB: ≥335 mL/day vs. none
ASB: ≥335 mL/day vs. none
SSB: ≥335 mL/day vs. none







Age, BMI, EI, PA, alcohol,
race, fruit and vegetables
consumption, menopause,
and HT. SSB were adjusted
for use of ASB and vice-versa.
Multiple myeloma 285
NHL 1324
McCullough et al., 2014
[40]
US,
CPS-II NCH NHL Cohort
100,442
10 1196 47–95 F (57) Willett FFQ
ASB: >355 mL/day vs. none
SSB: >355 mL/day vs. none
RR: 0.92 (0.73–1.17)
RR: 1.10 (0.77–1.58)
Education, race, WC, PA, BMI,
EI, DM, family history of
cancer, HTR and NSAIDs use,
cholesterol-lowering
medication, intake of alcohol,
read and processed meat,
milk, saturated fat, fruits and
vegetables, and tea and coffee.
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Upper Aerodigestive Cancers (Larynx, Oral Cavity, Oropharyngeal Squamous Cell, Pharynx)
Source Country, Study Name Cancer Type Study Design Population Follow-Up(Years) Cases
Age (Mean/SD
or Range) Sex (%)
Dietary Assessment
Method




Zvrko et al., 2008 [82] Montenegro Larynx HB case-control 2162 108 59.9 (9.7) M (82) DQ SB: yes vs. no OR: 0.38 (0.16–0.92)
Age, sex, smoking, alcohol,
coffee, diet, personal and
familiar medical history,
education, housing and work
conditions, and exposure to
toxic components.








50–71 M (59) 124-item FFQ
SB: ≥355 vs. ≤355 mL/day
SB: ≥355 vs. ≤355 mL/day




Age, sex, smoking, alcohol
drinking, BMI, EI, education,
ethnicity, PA, intake of fruit,
vegetables, and red and
white meat.
Lissowska et al., 2003
[83] Poland Oral cavity HB case-control 246 122 23–80 M (64) 25-item DQ FJ: >57 vs. <28.6 mL/day OR: 0.35 (0.15–0.80)
Age, sex, residence, drinking,
and smoking habit.
Kreimer et al., 2006 [84] 9 countries
‡ ,
IARC-MOCS OOSC HB case-control 3402 1670 NR M/F FFQ FJ: height vs. low intake OR: 0.8 (0.6–1.1)
Age, sex, country, education,
BMI, smoking, chewing, and
alcohol.
Other Cancers
Source Country, Study Name Cancer Type Study Design Population Follow-Up(Years) Cases
Age (Mean/SD
or Range) Sex (%)
Dietary Assessment
Method




Vincenti et al., 2008 [85] Italy Cutaneousmelanoma PB case-control 118 59 56 F (53) 188-item FFQ
FJ (no OJ): increase by 10 mL/day
OJ: increase by 10 mL/day
RR: 0.95 (0.87–1.03)
RR: 0.94 (0.88–1.00)
EI, family history of
melanoma, skin type, history
of sunlight exposure, and
sunburns.
Dubrow et al., 2012 [47] US Glioma Cohort 545,77110 904 62.8 (median) M (60) FFQ SB: >720 mL/day vs. none HR: 0.87 (0.65–1.15)
Age, sex, race, EI, height, fruit
and vegetables intake, and
nitrite intake from plants
Luqman et al., 2014 [86] Pakistan Lung HB case-control 1200 400 <40–>70 M (73) DQ J: yes vs. no OR: 0.3 (0.3–0.4) Not reported
Wu A. et al., 1997 [87] US Smallintestine PB case-control 1034 36 30–65 M (69) Interview SSB
7: daily vs. never OR: 3.6 (1.3–9.8) Age, ethnicity, and sex.




Thyroid Cohort 477,20611.4 748 51 F (70) DQ- country specific
FJ 1: > 94 vs. < 1 mL/day
FJ 1: increase by 50 mL/day
HR: 1.23 (0.98–1.53)
HR: 1.02 (0.99–1.06)
Age, sex, smoking status, BMI,
EI, alcohol, PA, education,
center, menopausal status and
type, OC use, and infertility
problems.
Overall Cancers
Source Country, Study Name Cancer Type Study Design Population Follow-Up(Years) Cases
Age (Mean/SD
or Range) Sex (%)
Dietary Assessment
Method




Bassett et al., 2020 [50] Australia, MCCS Non-obesityrelated * Cohort
35,109
19 4789 27–76 F (61) 121-item FFQ
SSB: >375 vs. none or < 12.5 mL/day
ASB: >375 vs. none or < 12.5 mL/day
HR: 1.02 (0.86–1.21)
HR: 1.23 (1.02–1.48)
Alcohol, country of birth,
Med-diet score, PA,
socio-economic position, sex,
and smoking. ASB also
adjusted for SSB intake.
Nutrients 2021, 13, 516 14 of 28
Table 1. Cont.





4 565 54.3 F (53) FFQ
SFJ: >501 vs. <73.2 mL/day
SSB:>180 mL/day vs. none




Age, sex, EI, alcohol, smoking,
and BMI.
Hodge et al., 2018 [54] Australia, MCCS Obesity-related Cohort 35,59319 3283 54.6 F (100) 121-item FFQ
SSB: ≥200 vs. <6.7 mL/day




country of birth, alcohol,
smoking, PA, Med-diet score,
and sex. ASB also for SSB
consumption and WC.







5.1 (median) 2193 42.2/14.4 F (78) 24H-DR
SFJ: >141.7 vs. <46.1 mL/day (cut-off)
SFJ: increase by 100 mL/day
SSB: >65.5 vs. <14.0 mL/day (cut-off)
SSB: increase by 100 mL/day
ASB: >7.9 vs. <2.7 mL/day (cut-off)
ASB: increase by 10 mL/day
FJ: >97.8 vs. <19.9 mL/day (cut-off)









Smoking, education, PA, BMI,
and height.
+ Expressed in milliliter (mL) per day (d) or week (wk) or none (nonconsumers). † Denmark, France, Germany, Greece, Italy, Norway, Spain, Sweden, The Netherlands, and the United Kingdom. ‡ Italy, Spain,
Poland, Northern Ireland, India, Cuba, Canada, Australia, and Sudan. * All identified cancers except esophagus (adenocarcinoma), pancreas, colorectum, breast (post-menopausal), endometrium, kidney, ovary,
gallbladder, liver, gastric cardia, meningioma, thyroid, multiple myeloma. 1: Fruit juice and vegetables juice. Vegetables juice <2%. 2: Colas. 3: Colas and root beer. 4: Not carbonated beverages. 5: Sugarcane juice
(20.3%), honeydew melon juice (14.1%), apple juice (12.8%), watermelon juice (9%), carrot juice (9%), pineapple juice (6.4%), star fruit juice (5.1%), and lemon juice drink (5.1%). The remaining canned grape,
tomato, and prune juice, along with papaya, plum, and fresh celery juice, each comprised 1.3–2.6% of the total juice consumption reported. 6: Fruit juice and nectars. 7: Carbonated beverages. AA: African
American; AEGJ: adenocarcinoma of the esophagus-gastric junction; ASB: artificially sweetened beverages; BC: breast cancer; BF: breastfeeding; BMI: body mass index; BWHS: Black Women’s Health Study; Caff:
caffeinated; CI: confidence interval; COSM: Cohort of Swedish Men; CPS-NCS: Cancer and Prevention Study, Nutrition Cohort Study; CR: colorectal; CVD: cardiovascular disease; EA: European American; EAC:
esophageal adenocarcinoma; EI: energy intake; EPIC: European Prospective Investigation into Cancer and nutrition; DH: diet history; DM: diabetes mellitus; DQ: dietary questionnaire; 24H-DR: 24 h dietary
recall; F: female; FFQ: food frequency questionnaire; FJ: natural fruit juice; GI: glycemic index; HB: hospital-based; HCC: Hepatocellular Carcinoma; HCS: Hokkaido Cohort Study; HPFS: Health Professionals
Follow-up Study; HPV: Human Papilloma Virus; HR: hazard ratio; HRT: hormone replacement therapy; HT: hypertension; IARC-MOCS: International Agency for Research on Cancer, Multicenter Oral Cancer
Study; IHBT: intrahepatic biliary tract; J: natural fruit and vegetable juice; M: male; MCCS: Melbourne Collaborative Cohort Study; MDC: Malmö Diet and Cancer; Med: Mediterranean; MS: menopausal status;
NCFD: not carbonated fruit drinks; NCSC: Nutrition Canada Survey Study; NHL: non-Hodgkin lymphoma; NNS: Nutri Net-Santé; NIH-AARP-DHS: National Institute of Health-American Association of
Retired Persons, Diet and Health Study; NSAIDs: nonsteroidal anti-inflammatory drugs; NHS: Nurses’ Health Study; OC: oral contraceptive; OJ: orange juice; OOSC: oral and oropharyngeal squamous cell; OR:
odds ratio; PA: physical activity; PB: population-based; PC: prostate cancer; Post-M: post-menopausal breast cancer; PSA: prostate-specific antigen; Pre-M: pre-menopausal breast cancer; Q: quantitative; Q1: first
quartile; Q4: quartile four; RR: relative risk; SB: total sweetened beverages, sugar and artificially sweetened beverages; SCC: squamous cell carcinoma SCHS: the Singapore Chinese Health Study; SD: standard
deviation; SFQ: structured food questionnaire; SFB: San Francisco Bay Study: SFJ: beverages high in sugar, added or natural, SSB + FJ; SSB: sugar-sweetened beverages; SMC: Swedish Mammography Cohort; SQ:
semiqualitative; SUVIMAX: Supplementation en Vitamines et Mineraux Antioxydants Study; UBC: urinary bladder cancer; UP: ultraprocessed; US: the United States; WC: waist circumference; WCHS: Women’s
Circle of Health Study.
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Table 2. Summary of the results of the meta-analysis (random effects model).
Cancer Type Exposure
N◦ of Studies





Breast SSB 4 3 1.14(1.01−1.30) 0.0 0.0073 0.69 0.88, 1.47
Breast FJ 3 0 1.13(0.93−1.38) 0.0 0.0017 0.79 0.52, 2.46
Breast Pre-M SSB 3 2 1.37(0.99−1.88) 55.7 0.0358 0.06 0.68, 2.76
Breast Post-M SSB 4 2 1.18(0.79−1.75) 54.8 0.1080 0.05 0.43, 3.23
Colorectal SSB 4 0 1.18(0.99−1.41) 0.0 0.0039 0.71 0.82, 1.69
Colorectal FJ 2 2 0.79(0.16−3.87) 88.5 0.8629 <0.001 0.008, 73.94
Colorectal * FJ 2 1 1.29(0.78−2.12) 0.0 0.0120 0.63 0.17, 9.81
Colorectal SB 0 3 2.02(0.45−9.01) 62.9 0.2711 0.07 0.00, 5753.1
Colorectal * SB 0 2 1.57(0.74−3.35) 0.0 0.0010 0.67 –
Bladder SB 0 5 1.66(0.78−3.56) 83.4 0.3226 <0.001 0.22, 12.37
Bladder * SB 0 4 1.27(0.85−1.90) 25.3 0.0425 0.26 0.45, 3.60
Prostate SSB 5 0 1.18(1.10−1.27) 0.0 0.0012 0.92 1.03, 1.35
Prostate FJ 4 0 1.03(1.01−1.05) 0.0 0.0001 0.93 0.98, 1.09
Prostate SB 1 2 0.97(0.56−1.69) 2.9 0.0241 0.36 0.07, 12.7
Renal cell SB 1 2 1.44(0.46−4.50) 65.4 0.1559 0.056 0.00, 604.16
Pancreatic SB 4 4 1.28(0.95−1.72) 58.6 0.0962 0.02 0.56, 2.90
Pancreatic SSB 4 2 1.01(0.92−1.11) 0.0 0.0016 0.92 0.87, 1.17
Pancreatic ASB 3 2 1.07(0.77−1.48) 43.6 0.0480 0.13 0.48, 2.36
* Results excluding outliers; + p values of Cochran’s Q-test heterogeneity. ASB: artificial sweetened beverage; FJ: fruit juice; PI: prediction
intervals; Post-M: post-menopausal; Pre-M: pre-menopausal; RR: risk ratio; CI: confidence interval; SB: sweetened beverage (including both
SSBs and ASBs); SSB: sugar-sweetened beverage.
3.2. Sweet Beverages and Risk of Breast Cancer
Nine publications reported data on breast cancer, four case-control [57,58,69,80] and
five cohort studies [23,51–53,55]. In the meta-analysis with six publications, including
four cohort studies [23,52,53,55] and two case-controls [57,80], a significant positive associa-
tion between high SSB consumption and breast cancer risk was observed (RR: 1.14, 95% CI:
1.0–1.3) (Table 2). No associations were found for FJ intake (Table 2). Marzbani et al. [58]
reported a positive association with SBs (OR: 2.8, 95% CI: 1.9–4.3), but no associations
were found for ASBs. Subgroup analyses for SSB consumption did not explain further
heterogeneity (Table S1).
3.2.1. Sweet Beverages and Risk of Pre-Menopausal Breast Cancer
Three cohort publications [23,53,55] and one case-control (taken as two as indices
were separated by ethnicity) [57] were included in the analysis of SSB intake and pre-
menopausal breast cancer. Their pooled analysis showed a borderline statistically non-
significant positive association (RR: 1.37, 95% CI: 0.99–1.88) (Figure S1), which reached
the significance in the subgroup analysis including only cohort studies (RR: 1.60, 95% CI:
1.08–2.37) (Table S1). A cohort study from 2019 [23] also reported data for ASB, FJ and SFJ
intake and only indicated a positive association for SFJs (HR: 1.28, 95% CI: 1.09–1.83).
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3.2.2. Sweet Beverages and Risk of Post-Menopausal Breast Cancer
A meta-analysis of four cohort studies [23,53–55] and one case-control (taken as
two as indices were separated by ethnicity) [57] of SSBs showed non-significant results
(Table 2). We performed subgroup analyses based on study design, country, and beverage
intake categories. No statistically significant results were found from the heterogeneity
test between groups (Table S1). Chazelas et al. [23] investigated the relationship with
SFJ consumption and observed a positive association (HR: 1.44, 95% CI: 1.05–1.99). No
significant results were reported for ASBs.
3.3. Sweet Beverages and Risk of Intestinal and Colorectal Cancer
Eight publications reported data on colorectal cancer, four case control [88–91] and
four cohort studies [23,52,54,56]. A borderline positive association was observed with
SSB intake using the random-effect model (RR: 1.18, 95% CI: 0.99−1.41) (Figure S1). No
significant results were found either for SBs or for FJs (RR: 2.02, 95% CI: 0.45−9.01 (SB); RR:
0.79, 95% CI: 0.16−3.87 (FJ) (Figure S2). After the exclusion of one outlier, results for the
random-effect model remained non-significant. No associations were found for colorectal
cancer risk and ASBs. With regard to rectal cancer, no associations were observed with
ASBs, SSBs or fruit and vegetables juices [92]. A case-control study on small intestine
cancer [65] indicated a significant positive association with SSB consumption (OR: 3.6,
95% CI: 1.3−9.8).
3.4. Sweet Beverages and Risk of Esophageal Cancer
Three publications, one cohort [34] and two case-control studies [59,93] reported data
on different types of esophageal cancers, including esophagus-gastric junction, esophageal
adenocarcinoma and squamous cell carcinoma. No significant associations were shown
between SB, SSB and ASB consumption and esophageal cancers risk.
3.5. Sweet Beverages and Risk of Gastric Cancer
One case-control [59] and two cohort studies [34,54] reported data on different types
of gastric cancer (overall, cardia and non-cardia) and SBs, ASBs or SSBs showing no
significant associations.
3.6. Sweet Beverages and Risk of Pancreatic Cancer
Eleven publications, six cohort [41–45] and five case-control studies [76–79,81] re-
ported data on pancreatic cancer. No significant results were observed for SBs, SSBs or
ASBs (Table 2). Although high heterogeneity was observed for SBs (I2 = 58.6, p = 0.02)
and ASBs (I2 = 43.6, p = 0.13) (Table 2), after performing subgroup analyses results slightly
improved but remained non-significant (Table S1). No association was observed between
FJ intake and pancreatic cancer risk.
3.7. Sweet Beverages and Risk of Genitourinary Cancer
3.7.1. Bladder
Six case-control studies [60–65] reported data on bladder cancer. No association
between SB consumption and bladder cancer risk was observed in the random-effect
meta-analysis including five case-control studies [61–65] (Figure S2). We observed a high
heterogeneity in the meta-analysis (I2 = 83.4%, p = 0.0001). Although heterogeneity was
reduced after excluding outliers and doing subgroup analyses, the associations were
positive but non-significant (Table S1). A US study suggested a statistically significant
relation between SB intake and bladder cancer risk [65]. Two case-control studies [60,65]
also considered SSBs and ASBs separately. In a Chinese case-control study [62], SSB intake
was suggested as a risk factor for bladder cancer, although no association was found for
FJs. Similarly, in a Serbian study [63], no significant association was observed between FJs
and bladder cancer risk.
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3.7.2. Prostate
Eight publications, six cohorts [23,31,35,36,52,54] and two case-controls [66,67] showed
data on prostate cancer. No significant associations were reported for SBs from quantitative
analysis. However, positive relations were observed in the random-effect model for SSBs
(RR: 1.18, 95% CI: 1.10−1.27) and FJs (RR: 1.03, 95% CI: 1.01−1.05). The results remained
the same in a subgroup analysis with 3 non-US (France, Spain, Australia) studies (RR: 1.13,
95% CI: 1.03−1.24) (Table S1). Two cohorts [23,54] reported data on ASB intake and only
one [23] found an increased prostate cancer risk of 33% (HR: 1.33, 95% CI: 1.01−1.75).
3.7.3. Renal and Urothelial Cell Cancer
Four publications, two case control [68,70] and two cohort studies [37,54] provided
data on renal cell cancer. For our meta-analysis, we selected three publications, two
case-control [68,70] and one control study [37] on SBs, but the random-effect meta-analysis
showed non-significant results (Table 2). Despite observing a high heterogeneity
(I2 = 65.4%, p-value = 0.058), no outliers were found, and the number of studies was too
low to perform subgroup analyses (n = 3). One case control study [70] reported a positive
association with the intake of ASBs (OR: 2.7, 95% CI: 1.1−6.5) but not the other two [37,54].
No significant results were reported for SSBs or FJs, despite one case-control [68] finding
a positive association with the consumption of fruit and vegetable juices taken together
(OR: 1.53, 95% CI: 1.18−1.99). The EPIC cohort study [38] reported data on urothelial cell
cancer and its association with SBs and FJs. A significant positive association was found
only with FJ intake (HR: 1.32, 95% CI: 1.05−1.66).
3.8. Sweet Beverages and Risk of Gynecological Cancers
Two case-control studies [71,72] investigated the relationship between FJ intake and
cervical cancer risk. Only one of them [72] found an inverse association (RR: 0.3, 95% CI:
0.2−0.6). Two cohort studies [39,54] reported data on different types of beverages (SSBs,
ASBs, FJs and SFJs) and endometrial cancer risk. Only one of them [39] found significant
positive associations with both SSBs (HR: 1.78, 95% CI: 1.32−2.40) and SFJs (HR: 1.48,
95% CI: 1.09−2.00). Finally, three case-control studies [69–71] reported data on epithelial
ovarian cancer risk. Only one of them [71] found positive associations for caffeinated
(OR: 1.51, 95% CI: 1.03−2.22) and non-caffeinated SBs (OR: 2.60, 95% CI: 1.25−5.36). No
significant associations were reported for ovarian cancer risk [50].
3.9. Sweet Beverages and Risk of Hepatobiliary Cancers
Two cohort studies [28,49] reported data on different types of sweet beverages and
various types of hepatobiliary cancers. The EPIC cohort [28] found no significant results
regarding the consumption of either SBs or FJs and biliary tract cancer risk. However, a
positive association was observed between both SBs (HR: 1.89, 95% CI: 1.11−3.02) and FJs
(RR: 1.03, 95% CI: 1.01−1.06) and hepatocellular carcinoma risk. The Swedish Mammogra-
phy Cohort and the Cohort of Swedish Men [49] found significant positive associations
with both gallbladder (HR: 2.24, 95% CI: 1.02−4.89) and extrahepatic biliary tract cancer
risks (HR: 1.79, 95% CI: 1.02−3.13). No significant results were reported for intrahepatic
biliary tract cancer risk.
3.10. Sweet Beverages and Risk of Hematologic Cancers
One cohort study [24] reported data on leukemia and multiple myeloma and its
association with SSB and ASB intake. Significant associations were found between the
consumption of ASBs and leukemia risk (RR: 1.42, 95% CI: 1.00−2.02). No associations were
observed in two cohorts [24,40] as regards SSBs or ASBs and non-Hodgkin lymphoma risk.
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3.11. Sweet Beverages and Risk of Upper Aerodigestive Cancers
Four studies [34,82–84] reported data on upper aerodigestive cancers. One US-based
cohort [34] showed no significant association between SB intake and pharyngeal, laryn-
geal and oral cavity cancer risks. A case-control study from Montenegro [82] suggested
an inverse relation between SBs and larynx cancer risk. The consumption of FJs was
inversely associated with oral cavity cancer risk in one case-control study [83] though not
in another [84].
3.12. Sweet Beverages and Risk of Other Cancers
Single studies reported data on different types of cancer and their link with sweet bev-
erages. No significant associations were reported for cutaneous melanoma [85], glioma [47]
or thyroid cancer risk [48] and any type of sweetened beverages. One case-control study [86]
reported an inverse association between natural juices (fruit and vegetables) and lung can-
cer risk (OR: 0.3, 95% CI: 0.3−0.4).
3.13. Sweet Beverages and Risk of Overall Cancer
An Australian cohort [50] investigated the association between SSBs and ASBs and
the risk of non-obesity-related cancers; they reported a positive association only with ASBs
(HR: 1.23, 95% CI: 1.02−1.48). Two cohorts [23,52] assessed the relationships between the
intake of several types of sweet beverages and obesity-related cancer risk. Only one of
them [23] showed positive associations with SSBs (HR: 1.06; 95% CI: 1.02−1.21), FJs (HR:
1.14, 95% CI: 1.01−1.29) and SFJs (HR: 1.30, 95% CI: 1.17−1.52). No association was found
for ASBs and obesity-related cancer risk.
3.14. Quality of Included Studies
According to the ROBINS-E tool (Figure 2a, Table S2), 13 of 27 cohort studies presented
a moderate overall risk of bias. This is due to some bias being detected mostly in the
classification of the exposure domain, deviation from the intended intervention and missing
data. Missing data bias was not evaluated for 5 cohorts [36,39,43,51,52], as the publications
did not report enough information. All studies fulfilled the criteria of low risk of bias
for selection of participants’ domain. In addition, 3 [36,37,54] of 27 studies did not adjust
the statistical analysis for all potential confounders. Therefore, they were classified at
moderate risk of bias. Only one study [50] was classified as moderate risk of bias for
outcome measurement, and another [56] for the selection of reported outcomes.
According to the NOS (Figure 2b, Table S3) most of the case-control studies (29 of
37) presented a moderate overall risk of bias; 7 publications presented a serious risk,
whereas 1 indicated a low risk. The risk of bias due to the selection of the groups was
classified as moderate for 35 studies, high for 2 [58,82] and low for another 2 [59,66]. Most
of the case-control studies adjusted their results for relevant and additional confounders
and were classified as moderate or low risk of bias for comparability between groups.
In addition, 5 were considered as serious risk for this domain, because 4 of them did
not adjust for all important confounders [60,63,66,92] and 1 [79] reported results from an
unadjusted analysis. Moreover, 5 studies [81,86,88,89] did not report this information and
were classified as ‘no information’ category. The risk of bias due to ascertainment of the
exposure was considered moderate in all case-control studies.
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4. Discussion
4.1. Association between Consumption of Sweet Beverages and Cancer Risk
The aim of this study was to assess the relationships between different groups of
sweet beverages and site-specific or overall cancer risk. We conducted a meta-analysis
when at least three studies reported data for the same exposure (sweet beverage type) and
outcome (cancer site). We found several statistically significant and borderline positive
associations between the consumption of SBs, especially SSBs, and in some cases ASBs or
FJs, and several cancer risks.
Regarding breast cancer, the meta-analysis showed a positive association using ran-
dom effects, with a 14% higher risk for SSBs, but non-statistically significant results for
pre- and post-menopausal breast cancer. However, after performing subgroup analyses
by study type, cohort studies showed significant positive results for pre-menopausal
breast cancer and SSBs. Chazelas et al. [23] reported a positive linear trend between SSB
intake and breast/pre-menopausal breast cancer risk when SSB consumption increased
by 100 mL/day. In line with our results, current evidence supports the World Cancer
Research Fund/American Institute for Cancer Research (WCRF/AICR) recommendations
of reducing or avoiding SSB intake for breast cancer prevention [94]. One US case-control
study [57] conducted a separate analysis for African-American and European-American
women. This showed a positive link between SSB intake and post-menopausal breast
cancer risk for European-American women only. Likewise, two other cohorts that included
mostly Caucasian women [53,54] showed similar results. This evidence suggests that
ethnic differences may play a role. However, we could not explore this association as
no other studies included women of African descent. In fact, evidence on the role of
nutritional factors in breast cancer for this population is limited and inconclusive [95]. Our
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meta-analysis did not find significant associations between FJs and breast cancer risk. With
regards to the SFJ group, comparing highest versus lowest consumption, Chazelas et al. [23]
reported positive relations for SFJs and total, pre- and post-menopausal breast cancer risk.
Conversely, Makarem et al. [52] showed no significant associations. A publication from
the US [69] found no positive associations for SBs and breast cancer risk; however, a recent
case-control study [58] found positive associations.
For colorectal cancer risk, our meta-analysis found no positive results using random
effects for SB, SSB or FJ intake. Despite having performed secondary analyses excluding
outliers and having explained between-studies heterogeneity, results for the random-effect
model remained non-significant. This is in a way consistent with results from a previous
meta-analysis, which found no association between SSBs and colon cancer risk using a
random-effects model [21]. On the other hand, a cohort study from 2014 found a positive
association for an increase in 330 mL/day of SSBs [91]. Likewise, an Australian study that
compared extreme categories of SSB intake (≥200 mL/day versus <6.7 mL/day) showed
positive results [54]. We included only one study assessing rectal cancer incidence [92].
Here, a separate analysis for women and men was performed. The majority of the results
were not significant, and the only positive association was found for juice (fruit and
vegetables) consumption in female participants.
In regard to esophageal cancers, publications included in this review were also part of
a meta-analysis from 2014 [18]. This meta-analysis reported no association between SBs and
esophageal adenocarcinoma and squamous cell carcinoma risk. After extracting separated
data for SSB and ASB intake, we found similar results. Despite these observations, positive
associations were found in a pooled analysis of US-based case-control studies. This study
assessed the association between sugar dietary intake and Barret’s esophagus incidence, a
precursor for esophageal adenocarcinoma tumor [96]. Even though data from the included
studies reported non-significant results for stomach cancer incidence, a Japanese cohort
study observed that carbonated drinks and juices appeared to be related to an elevated risk
of death from stomach cancer [97].
With respect to pancreatic cancer, we performed a meta-analysis for SBs, SSBs and
ASBs. These associations, especially for SBs, tended to be positive but did not reach
statistically significant levels using random effect models. These results go along with a
recent meta-analysis from 2019 [19] which also showed no association between SB intake
and pancreatic cancer risk. Besides that, a pooled analysis from 2012 [20] reported a 56%
higher risk of pancreatic cancer for males consuming ≥375 mL/day of SSBs compared to
non-consumers. Likewise, a Swedish cohort [41] found a 93% higher risk of pancreatic
cancer incidence among those who consumed ≥500 mL/day of SSBs compared to non-
consumers. However, we performed a subgroup analysis taking into account beverage
intake category (high vs. non- consumer), but no significant associations were observed
(Table S1). In addition, only one study reported separate results for carbonated and
noncarbonated SBs, but no significant results were shown [76].
For bladder cancer risk, 3 out of the 6 included case-control studies [62,63,65] showed
positive associations for highest versus lowest amounts of SB intake. However, the meta-
analysis of these studies together with 2 other case-control studies [61,64] showed no
significant associations. Despite performing a second analysis excluding one study that
presented some serious bias, the results remained non-significant (Table S1). Hence, our
meta-analysis of observational studies reported that SBs appeared to be unrelated to
bladder cancer risk. It is not clear how SSBs, ASBs or FJs act in isolation as the evidence
is limited.
With reference to prostate cancer, our meta-analysis demonstrated an 18% higher risk
for SSBs comparing the highest with the lowest intake. Similarly, we found a small positive
association for FJs (a 3% higher risk). No associations were found for SBs, which may
suggest that the role of ASBs might not be relevant. However, one study [23] reported a
positive association between ASB intake and prostate cancer risk.
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Renal cell cancer appeared to be unrelated to SB consumption according to the meta-
analysis results. We observed a high between-study heterogeneity (I2= 65.4%). However,
not enough studies (n = 3) were included to perform subgroup analyses. Even so, Maclure
and Willet [70] reported a significant positive association between highest versus lowest
SB intake and renal cell cancer risk (RR: 2.6, 95% CI: 1.4−4.8). More studies analyzing this
association are required for further clarification.
The association between SSB consumption and both endometrial and ovarian cancer
risk tended to be positive but did not reach statistically significant levels. One study
stratified results by types of endometrial cancer (I and II) [39]. They reported positive
associations between highest versus lowest SSB and SFJ consumption and endometrial type
I cancer in post-menopausal women, but not in type II. These might be because subtypes
may have different risk factors, even though evidence on this etiologic heterogeneity is
quite limited [98]. Data from two studies [71,72] suggested that FJ intake might be a
protective factor for cervical cancer. FJ consumption is often considered part of a healthy
diet and lifestyle [99]. However, none of the mentioned studies [71,72] adjusted for such
confounders. Thus, it is not clear if the protective effect was due to FJ intake or other factors.
For epithelial ovarian cancer, one US study [75] stratified the results by caffeinated and non-
caffeinated colas. Both results were positive statistically significant, but non-caffeinated
colas showed a stronger association. Although this might suggest a protective effect of
caffeine, a recent meta-analysis of prospective studies found no link between caffeine intake
and ovarian cancer risk [100].
In respect of hepatobiliary cancers, data from the included studies showed a posi-
tive association with SB consumption, especially for gallbladder cancer, where the risk
was doubled [49]. This might be explained by the detrimental association between su-
crose/glycemic load and the increased risk of symptomatic gallstone disease [101], which
is strongly correlated with gallbladder cancer [102]. Stepien et al. [28] showed slightly
positive dose–response associations between SBs, ASBs or FJs and HCC incidence.
As regards hematologic cancers, no associations were found either for sugary or for
artificially sweetened beverages, except for leukemia risk, for which one study [24] reported
significant positive associations with ASBs. However, a recent review of clinical trials and
observational studies observed no association between artificial sweeteners intake and
both leukemia and non-Hodgkin lymphoma incidence [103].
The evidence is more limited regarding cancer of the oral cavity, pharynx, larynx, lung,
thyroid, glioma and cutaneous myeloma. The available data mainly showed nonsignificant
results for SB and FJ intake. Only one study from Montenegro indicated an inverse
association between SB intake and laryngeal cancer risk [82]. However, the results from this
study should be treated with caution as they presented some methodological inadequacies
and its overall risk of bias was classified as ‘serious risk’ (Table S3). One case-control study
from 1997 observed a strong positive association between small intestine cancer risk and
SSBs (OR: 3.6, 95% CI: 1.3−9.8), although further high quality evidence is needed [87]. One
study that reported incidence of overall non-obesity-related cancers showed no association
for SSBs but a positive association for ASBs [50]. Moreover, the largest of 3 studies [23,52,54]
on overall obesity-related cancer risk showed positive associations with SFJs, SSBs and
FJs, but not with ASB consumption [23]. Similarly, a meta-analysis of clinical trials and
observational studies showed no association between artificial sweetener intake, body
weight and different types of cancers [103]. Our findings are in accordance and we agree
with the previous study [103] upon the uncertainty of the evidence that links artificial
sweeteners with different types of cancer.
4.2. Limitations of the Current Data
To the best of our knowledge, this is the first systematic review to evaluate the
isolated association between different groups of sweet beverages and cancer risk. Several
limitations should be considered while interpreting our findings. Some studies included
in this systematic review were difficult to compare due to their design (cohort and case-
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control studies), methodology, classification and categories of beverages intake. Therefore,
it was a challenge to perform such comparisons. According to the ROBIN-E tool, cohort
studies were at low-moderate risk of bias. As per the NOS, the case-control studies
were at moderate risk of bias and 6 studies [58,60,66,79,82,86] out of 37 presented serious
methodology inadequacies. The number of publications included in most meta-analysis
was relatively low (between 3 and 6). On this basis, the pooled effect size was calculated
based on risk ratios of cohort and case-control studies together. Not having enough
studies was a major limitation to perform subgroup analyses when high between-study
heterogeneity was observed. Moreover, the small amount of studies may have been a
potential source of unexplained heterogeneity [104]. We did not have enough data to
perform subgroup analyses based on different population characteristics (e.g., sex, lifestyle
factors or history of cancer). However, we did perform subgroup analyses based on
geographical area.
The majority of the included participants were from the US or European countries.
Hence, extrapolating our findings to other geographical areas may not be appropriate.
We attempted to classify beverages into specific groups. However, some studies did not
report precise information on this topic, which might have given rise to misclassifications.
Similarly, we attempted to convert original exposure information into amounts of intake
(mL/day) based on national data. Nevertheless, this was not possible in all studies which
prohibited performance of a dose–response meta-analysis. Another limitation may be
the measurement error in collecting dietary data since self-reported questionnaires were
used. Moreover, in the longitudinal studies we were limited to the baseline estimation of
beverages consumption, and there is a possibility that their consumption changed over time.
It is suggested that the link between SSBs or FJs and cancer risk is possible due to their high
glycemic indexes [13] and to obesity-inducing pathways [4]. However, these variables were
not adequately integrated as confounders in all the studies. Indeed, glycemic index was
only considered in one cohort [53]. Despite BMI being a common indicator of obesity and
most studies considering it as confounder, only 4 of them [35,40,52,54] adjusted for other
obesity indicators such as waist circumference. Most of the studies assessed the association
between consumption of SSB and common cancers such as breast, colorectal, prostate and
pancreatic cancer. Data were more limited for FJs or ASBs and other types of cancers,
especially non-obesity-related ones. FJ consumption may coexist with healthy habits, such
as healthy diet or exercise [99]. Therefore, it would have been even better if some studies
had adjusted their analysis for such variables. In fact, only 3 publications [52–54] used diet
quality as a confounder.
5. Conclusions
The current meta-analysis of cohort and case-control studies indicated a statistically
significant positive association between higher consumption of SSB and breast and prostate
cancer incidence. As regard pre-menopausal breast cancer, results from cohort studies alone
showed a significant association. Likewise, it showed a statistically significant positive
link between high intakes of FJs and prostate cancer risk. Although the associations
between other sweet beverages and other cancer types were also positive, they did not
reach statistically significant levels. The small number of studies and cancer cases might
have been a reason why we did not find statistically significant results for several cancer
types. Study location (US/non-US, mostly European) did not appear to influence the
results. Current evidence indicates that higher incidence of some cancers is related to a
high consumption of SSBs. However, the evidence is limited to make recommendations
regarding ASBs and FJs. This subject requires further investigation.
We encourage future research in this field to perform more separated analysis on SSB,
ASB and FJ consumption. We believe it would be prudent to establish a homogeneous
classification of beverages in order to better understand their role in carcinogenesis. We
also recommend considering other obesity-related factors besides body mass index, such
as waist circumference, glycemic index and quality of diet as confounders. We could not
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study the different roles of non-carbonated soft drinks (sport, fruit and tea-based drinks),
sometimes used as healthier alternatives to carbonated drinks [105]. Therefore, it would be
advisable for future studies to further explore this research area.
This systematic review supports the WCRF/AICR recommendations to limit sugary
drinks consumption for cancer prevention [106] and to raise consumers’ awareness of
their low nutritional quality and high sugar content. We recommend replacement of
sweet beverages with plain safe drinking water and infusions without added sugars as
the main liquid source for body hydration. Even though some guidelines maintain that
moderate consumption of FJs may be part of a healthy diet [107], FJs contain little or no
dietary fiber and are positively associated with tooth decay in children [108]. Professional
societies have recently recommended limiting children’s FJ consumption as means of
addressing the obesity epidemic [3]. Whole fruits and plain safe drinking water should
also be affirmed as a healthier alternative to sweet beverages in adults. This would
aim to promote the appropriate consumption of essential nutrients, to reduce intake
of excessive sugars/calories and to therefore lower cardiometabolic disease and cancer
incidences [109,110]. The increase in cancer [25], obesity [111] and type 2 diabetes [112]
requires policy action. We recommend policymakers worldwide to consider (or continue
with) taxation and marketing restriction for sweet beverages, especially SSBs.
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sweetened beverage (ASB) intake category.
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82. Zvrko, E.; Gledović, Z.; Ljaljević, A. Risk factors for laryngeal cancer in Montenegro. Arh. Hig. Rada Toksikol. 2008, 59, 11–18.
[CrossRef]
83. Lissowska, J.; Pilarska, A.; Pilarski, P.; Samolczyk-Wanyura, D.; Piekarczyk, J.; Bardin-Mikolajczak, A.; Zatonski, W.; Herrero, R.;
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